This review explores the changing landscape of drug safety in patients with cystic fibrosis (CF) prescribed Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapy. While serious adverse reactions are infrequent, they can necessitate treatment withdrawal and thereby negatively impact clinical outcomes. The CFTR correctors (vanzacaftor, elexacaftor, tezacaftor, lumacaftor) and potentiators (ivacaftor, deuterated ivacaftor) target the underlying CFTR defect to improve protein function. The CF patient population encounter a high prevalence of non-immediate adverse drug reactions and T-cell mediated hypersensitivity to
Keywords
